Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells

CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

(2016) Jae H. Park et al.   BLOOD

Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells

(2016) Mark B. Geyer et al.   CYTOTHERAPY

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

(2016) Omkar U. Kawalekar et al.   IMMUNITY

Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy

(2016) Mark O'Hara et al.   Immunotherapy

CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients

(2016) Cameron J. Turtle et al.   JOURNAL OF CLINICAL INVESTIGATION

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

(2016) Meenakshi Hegde et al.   JOURNAL OF CLINICAL INVESTIGATION

A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway

(2016) Jing Liu et al.   Journal of Hematology & Oncology

Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized

(2016) Zhiwu Jiang et al.   Journal of Hematology & Oncology

Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia

(2016) Bo Cai et al.   Journal of Hematology & Oncology

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

(2016) Yongxian Hu et al.   Journal of Hematology & Oncology

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy

(2016) Hanren Dai et al.   JNCI-Journal of the National Cancer Institute

Driving CAR T-cells forward

(2016) Hollie J. Jackson et al.   Nature Reviews Clinical Oncology

Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells

(2016) Fengtao You et al.   Science China-Life Sciences

Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells

(2016) Cameron J. Turtle et al.   Science Translational Medicine

GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways

(2016) Wei Ye et al.   Oncotarget

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy

(2016) Hanren Dai et al.   JNCI-Journal of the National Cancer Institute

Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy

(2016) Vita Golubovskaya et al.   Cancers

Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model

(2015) H Almåsbak et al.   GENE THERAPY

ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells

(2015) Y. Xiao et al.   HAEMATOLOGICA

Loss of Angiopoietin-like 7 diminishes the regeneration capacity of hematopoietic stem and progenitor cells

(2015) Yiren Xiao et al.   Journal of Hematology & Oncology

HER2/neu-directed therapy for biliary tract cancer

(2015) Milind Javle et al.   Journal of Hematology & Oncology

Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments

(2015) Wei Ye et al.   Journal of Hematology & Oncology

CD4+T Cell Help Selectively Enhances High-Avidity Tumor Antigen-Specific CD8+T Cells

(2015) Ziqiang Zhu et al.   JOURNAL OF IMMUNOLOGY

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

(2015) David M. Barrett et al.   JOURNAL OF IMMUNOLOGY

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

(2015) David L. Porter et al.   Science Translational Medicine

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors

(2015) A. Morello et al.   Cancer Discovery

ANGPTL7 regulates the expansion and repopulation of human hematopoietic stem and progenitor cells

(2015) Y. Xiao et al.   HAEMATOLOGICA

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells

(2014) S. Guedan et al.   BLOOD

Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice

(2014) Victoria Hillerdal et al.   BMC CANCER

A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma

(2014) Jianping Yuan et al.   Journal of Hematology & Oncology

Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor

(2014) S. Wilkie et al.   JOURNAL OF IMMUNOLOGY

Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane

(2014) S. E. James et al.   JOURNAL OF IMMUNOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

(2014) P. S. Adusumilli et al.   Science Translational Medicine

The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

(2014) M. Hudecek et al.   Cancer Immunology Research

CAR T cells: driving the road from the laboratory to the clinic

(2013) Eleanor J. Cheadle et al.   IMMUNOLOGICAL REVIEWS

Design and development of therapies using chimeric antigen receptor-expressing T cells

(2013) Gianpietro Dotti et al.   IMMUNOLOGICAL REVIEWS

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+T cells

(2012) Andreas A. Hombach et al.   OncoImmunology

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo

(2011) D.-G. Song et al.   BLOOD

CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients

(2011) Barbara Savoldo et al.   JOURNAL OF CLINICAL INVESTIGATION

Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response

(2010) A Hombach et al.   GENE THERAPY

Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo

(2009) Michael C. Milone et al.   MOLECULAR THERAPY

Chimeric Antigen Receptors Combining 4-1BB and CD28 Signaling Domains Augment PI3kinase/AKT/Bcl-XL Activation and CD8+ T Cell–mediated Tumor Eradication

(2009) Xiao-Song Zhong et al.   MOLECULAR THERAPY

Differential Cellular Internalization of Anti-CD19 and -CD22 Immunotoxins Results in Different Cytotoxic Activity

(2008) X. Du et al.   CANCER RESEARCH